The newer eczema drugs — the biologics Dupixent and Adbry and the oral JAK inhibitors Rinvoq and Cibinqo — work well but get denied constantly. Almost always for the same three fixable reasons: severity that wasn't documented, topical step therapy that's missing, and a prescriber who isn't a specialist. Check your situation against your plan's real criteria below. The tool also covers plaque-psoriasis biologics (Skyrizi, Cosentyx, Humira) and the non-steroidal creams (Opzelura, Eucrisa, Vtama, Zoryve) — switch the treatment in the checker.
These are high-cost specialty drugs, so plans wrap them in prior authorization. The good news: the rules are published and specific, so a denial is usually a documentation problem, not a dead end. Three gates decide most cases:
Two more that trip people up: you can't be on two systemic agents at once (another biologic or JAK for the same eczema), and the JAK inhibitors (Rinvoq, Cibinqo) carry a boxed safety warning, so plans add steps — often a biologic tried first, plus TB screening and baseline labs.
Most eczema-drug denials are overturned on appeal — and most overturns just need the missing documentation, not a fight. Read the denial letter for the exact reason (usually "step therapy not met" or "severity not documented"), have your dermatologist supply that specific piece, and file the internal appeal within the deadline. If it's upheld, you're entitled to an independent external review — through your state for a state-regulated plan, or the federal process for a self-funded employer or Medicare plan — generally within about four months of the final denial. Manufacturer programs (Dupixent MyWay, Rinvoq Complete) can bridge the cost while you appeal.
Answer a few plain questions about severity, the topicals you've tried, and who's prescribing, and see exactly what to document before the request is filed — about two minutes, free.
Check my coverageUsually one of three things: the chart didn't document moderate-to-severe disease with an objective measure (body-surface-area %, EASI, or IGA); you hadn't tried and failed two classes of topical treatment first (a topical steroid and a calcineurin inhibitor or Eucrisa); or the prescriber wasn't a dermatologist, allergist, or immunologist. All three are fixable with the right documentation, and most denials are overturned on appeal.
Topical step therapy. Plans generally require a documented trial of, and failure or intolerance to, two topical classes: a medium-to-high-potency topical corticosteroid and a topical calcineurin inhibitor (tacrolimus or pimecrolimus) or Eucrisa. For the JAK inhibitors Rinvoq and Cibinqo, many plans additionally want a biologic tried first, plus TB screening and baseline labs, because of the boxed safety warning.
Usually. Most plans only cover Dupixent, Rinvoq, Cibinqo and Adbry when a dermatologist, allergist, or immunologist prescribes them. If your primary-care provider wrote the prescription, the plan may deny it until a specialist prescribes or co-signs.
No. Plans cover only one systemic agent at a time for the same eczema — you can't be approved for Dupixent (or Adbry) at the same time as a JAK inhibitor like Rinvoq or Cibinqo for the same condition.
Good, if the clinical picture supports it. Most eczema-drug denials are overturned, and most overturns simply need the missing documentation added — the objective severity score, the record of the two topicals tried, or a specialist's sign-off. Use the exact reason in your denial letter, file the internal appeal on time, and escalate to an independent external review if it's upheld.
Related: Does insurance cover Dupixent? Full guide to denials & appeals · Is my drug on my plan's formulary? · Why prior authorizations get denied · Same drug, wrong form or dose — denied · all coverage tools